Shots:

• Verona Pharma to receive $40M including $25M upfront cash and $15M equity interest in Nuance Biotech- and is eligible to receive ~$179M in milestones along with royalties on net sales in Greater China (mainland China- Taiwan- Hong Kong and Macau)
• Verona Pharma granted Nuance Pharma exclusive right to develop & commercialize ensifentrine in Greater China and is currently evaluating the therapy in P-III program for COPD in US- EU & South Korea
• Nuance Pharma will be responsible for all costs related to clinical development & commercialization and plans to file a CT Application with CFDA in 2021 & starts clinical studies for COPD in Greater China thereafter

| Ref: PR Newswire | Image: PR Newswire